[1]Patent:WO2004/48382,2004,A1,.Locationinpatent:Page7
[2]JournalofMedicinalChemistry,2008,vol.51,#7,p.2302-2306
Title: In vitro and ex vivo anti-fibrotic effects of LY2109761, a small molecule inhibitor against TGF-β.
Journal: Toxicology and applied pharmacology 20180915
Title: Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Journal: BMC cancer 20150101
Title: Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.
Journal: Toxicology 20141204
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120701
Title: Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Journal: Bone 20120301
Title: Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Journal: Neoplasia (New York, N.Y.) 20110601
Title: Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.
Journal: Cancer research 20110315
Title: Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
Journal: Molecular cancer 20100101
Title: Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Journal: Hepatology (Baltimore, Md.) 20091001
Title: Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.) 20090301
Title: Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Journal: Journal of medicinal chemistry 20080410
Title: LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Journal: Molecular cancer therapeutics 20080401
Title: Melisi D, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther, 2008, 7(4), 829-840.
Title: Fransvea E, et al. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 2008, 47(5), 1557-1566.
Title: Zhang M, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res, 2011, 71(23), 7155-7167.
